Technical Analysis for SRPT - Sarepta Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 149.26 -1.56% -2.37
SRPT closed down 1.56 percent on Friday, July 19, 2019, on 1.11 times normal volume.

Earnings due: Aug 6

*** please verify all earnings dates ***
5 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical SRPT trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Multiple of Ten Bearish Other 0.00%
MACD Bearish Signal Line Cross Bearish -1.56%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.56%
Wide Bands Range Expansion -1.56%
Overbought Stochastic Strength -1.56%
NR7 Range Contraction -3.08%
Inside Day Range Contraction -3.08%
Wide Bands Range Expansion -3.08%
Overbought Stochastic Strength -3.08%

Older signals for SRPT ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:
Profile
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Biotechnology Biopharmaceutical Life Sciences Biology Infectious Diseases Rare Diseases Duchenne Muscular Dystrophy Therapeutic Gene Modulation Antisense RNA
Is SRPT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jul 18 Is Sarepta Therapeutics (SRPT) Stock Outpacing Its Medical Peers This Year?
Jul 17 The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On
Jul 17 Sarepta vs Pfizer: Which Stock Should Investors Buy?
Jul 12 ICER report cites continued lack of evidence supporting efficacy of exon-skipping therapies for DMD
Jul 12 Sarepta Therapeutics Looks Ready to Break Out to the Upside
Jul 11 Sarepta Soars As Pfizer's DMD Prospects Languish
Jul 10 Sarepta Gains After Pfizer Suffers A Setback With Gene Therapy For DMD
Jul 9 Sarepta up 2% premarket as MS boosts target
Jul 8 Biophytis files for 8.75M-share U.S. IPO at $7-$9/ADS
Jul 8 Sarepta Stock Up Almost 40% This Year So Far: Here's Why
See more SRPT news...
Indicators
Indicator Value
52 Week High 165.87
52 Week Low 95.21
Average Volume 1,147,828
200-Day Moving Average 126.8145
50-Day Moving Average 131.0902
20-Day Moving Average 146.206
10-Day Moving Average 152.323
Average True Range 5.4833
ADX 25.68
+DI 26.7599
-DI 23.8293
Chandelier Exit (Long, 3 ATRs ) 142.3501
Chandelier Exit (Short, 3 ATRs ) 140.2399
Upper Bollinger Band 168.002
Lower Bollinger Band 124.41
Percent B (%b) 0.57
BandWidth 29.815466
MACD Line 6.7269
MACD Signal Line 7.3672
MACD Histogram -0.6403
Fundamentals Value
Market Cap 9.59 Billion
Num Shares 64.2 Million
EPS -2.34
Price-to-Earnings (P/E) Ratio -63.79
Price-to-Sales 53.98
Price-to-Book 6.98
PEG Ratio 231.25
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 157.90
Resistance 3 (R3) 157.88 154.98 156.46
Resistance 2 (R2) 154.98 152.78 154.99 155.98
Resistance 1 (R1) 152.12 151.43 150.67 152.14 155.50
Pivot Point 149.23 149.23 148.50 149.23 149.23
Support 1 (S1) 146.36 147.03 144.92 146.38 143.02
Support 2 (S2) 143.47 145.67 143.48 142.54
Support 3 (S3) 140.61 143.47 142.06
Support 4 (S4) 140.62